Is there an optimal treatment scheme for adjuvant intravesical therapy? Preliminary analysis of an EORTC protocol comparing early and delayed instillation with and without maintenance of either adriamycin or mitomycin-C in patients with superficial transitional carcinoma of the bladder

Prog Clin Biol Res. 1988:269:525-37.
No abstract available

Publication types

  • Clinical Trial
  • Comparative Study
  • Controlled Clinical Trial

MeSH terms

  • Administration, Intravesical
  • Carcinoma, Transitional Cell / drug therapy*
  • Carcinoma, Transitional Cell / surgery
  • Clinical Trials as Topic
  • Combined Modality Therapy
  • Doxorubicin / administration & dosage*
  • Doxorubicin / therapeutic use
  • Follow-Up Studies
  • Humans
  • Mitomycin
  • Mitomycins / administration & dosage*
  • Mitomycins / therapeutic use
  • Neoplasm Recurrence, Local / prevention & control*
  • Random Allocation
  • Time Factors
  • Urinary Bladder Neoplasms / drug therapy*
  • Urinary Bladder Neoplasms / surgery

Substances

  • Mitomycins
  • Mitomycin
  • Doxorubicin